Lower incidence of CMV infection and acute rejections with valganciclovir prophylaxis in lung transplant recipients

Table 3 Episodes of CMV infection or disease during the first 12 months in 88 CMV- seropositive (R+) lung transplant recipients

CMV infection or disease	Oral ganciclovir 3 months	Valganciclovir 3 months	p-value
(n %)	n = 37	n = 51
LTx, years	2001-2003	2004-2006
No CMV, n (%)	17 (46)	39 (76)
CMV infection/disease, n (%)	20 (54)	12 (24)	0.003
CMV disease -Total n (%)	12 (33)	10 (20)	0.170
-Severe	0	2 (4)	0.262
-Moderate	8 (22)	5 (10)
-Mild	4 (11)	3 (6)
Asymptomatic CMV inf., n (%)	8 (22)	2 (4)	0.005
Prolonged CMV episode, n (%)	1 (3)	2 (4)	0.756
Gastrointestinal CMV inf., n (%)	2 (5)	2 (4)	0.741
Ganciclovir resistance, n (%)	0	1 (2)	0.392
Onset of CMV inf/disease, days,			0.188
Median, mean	174,163	154,136^a	0.188
(range)	(100-270)	(23-201^a)

^aOnset of CMV infection was 62 days after transplantation for one patient who probably had a GCV resistant virus. Two patients had no or inadequate CMV prophylaxis owing to renal failure. Onset of CMV infection for these two patients was 23 days and 32 days after transplantation. For the remaining individuals in the VGCV group the onset of CMV infection/disease was on average 168 days after transplantation (range: 147 – 201 days).

ISSN: 1471-2334